Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
Ovid Therapeutics Inc. - Special Call
Ovid Therapeutics Inc. - Special Call Company Participants Victoria Fort - Senior Vice President of Corporate Affairs & Corporate Strategy Jeremy Levin - CEO & Chairman Meg Alexander - President & COO Conference Call Participants Laura Chico - Wedbush Securities Inc., Research Division Ritu Baral - TD Cowen, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division Myles Minter - William Blair & Company L.L.C.
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.12 per share a year ago.
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago.
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
